Search results
These Drugs Are the New First Line of Defense Against Migraine
Verywell Health via Yahoo News· 3 weeks agoIllustration by Julie Bang for Verywell Health Fact checked by Nick Blackmer Key Takeaways CGRP...
FDA Approves Zavzpret, a New Fast-Acting Nasal Spray to Treat Migraine
Health via Yahoo News· 1 year agoThe Food and Drug Administration (FDA) approved Zavzpret, a new nasal spray for the treatment of...
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
Zacks via Yahoo Finance· 2 years agoShares of Biohaven Ltd. BHVN surged 47.6% on Oct 5 on investors’ optimism about the company's new...
FDA Approves a New Nasal Spray to Treat Migraines
Time via Yahoo News· 1 year agoCredit - Getty Images On Mar. 10, the U.S. Food and Drug Administration (FDA) approved a new treatment for migraines given as a nasal spray, according to...
AbbVie (ABBV) Files Qulipta sNDA for Chronic Migraine Prevention
Zacks via Yahoo Finance· 2 years agoWith the latest approval for chronic migraine prevention, AbbVie's(ABBV) Qulipta becomes the only...
AbbVie's Migraine Treatment Scores Canadian Approval
Benzinga via Yahoo Finance· 1 year agoHealth Canada has approved AbbVie Inc's (NYSE: ABBV) Ubrelvy (ubrogepant) for the acute treatment of migraine, with or without aura, in adults. Ubrelvy...
Pfizer Buys Biohaven In A $12 Billion Deal That 'Couldn't Have Come At A Better Time'
Investor's Business Daily· 2 years agoPfizer will buy migraine drugmaker Biohaven Pharmaceuticals for nearly $12 billion in a deal "that...
AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine
Zacks via Yahoo Finance· 2 years agoAbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to...
FDA Expands AbbVie's (ABBV) Qulipta Label in Chronic Migraine
Zacks via Yahoo Finance· 1 year agoFollowing FDA's label-expansion approval, AbbVie's (ABBV) Qulipta is the first and the only oral...
Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret
Zacks via Yahoo Finance· 1 year agoZavzpret (zavegepant) is now part of Pfizer's (PFE) migraine drugs portfolio with the 2022...